SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gujarat Kidney jumps on inking pact to acquire 51% stake in Blue Tree Clinics

10 Jul 2026 Evaluate

Gujarat Kidney And Super Speciality is currently trading at Rs. 133.50, up by 2.65 points or 2.03% from its previous closing of Rs. 130.85 on the BSE.

The scrip opened at Rs. 131.25 and has touched a high and low of Rs. 138.00 and Rs. 130.95 respectively. So far 25956 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 148.45 on 25-May-2026 and a 52 week low of Rs. 98.25 on 23-Jan-2026.

Last one week high and low of the scrip stood at Rs. 138.00 and Rs. 126.80 respectively. The current market cap of the company is Rs. 1052.56 crore.

The promoters holding in the company stood at 71.45%, while Institutions and Non-Institutions held 5.44% and 23.10% respectively.

Gujarat Kidney and Super Speciality has entered into a stock purchase agreement with Blue Tree Clinics LLC, Dubai, to acquire 51% stake, through a purchase of equity shares from existing shareholders. Blue Tree Clinics LLC is a polyclinic duly licensed in Dubai, United Arab Emirates and is inter alia engaged in the business of registered activity as Plastic Surgery, Laser Cosmetic, General Dental Clinic and Chiropractic Centre.

The objective of the acquisition is the expansion of existing business of the company into new geographies and with a set of services other than that of provided by the company in India. The cost of acquisition is Rs 19.83 crore, payable in two tranches.

Gujarat Kidney and Super Speciality is one of the regional healthcare companies located in the central region of state of Gujarat and operate a chain of mid-sized multispeciality hospitals, providing integrated healthcare services, with a focus on secondary and tertiary care.

Guj. Kidney & Super Share Price

127.25 -0.15 (-0.12%)
23-Jul-2026 16:59 View Price Chart
Peers

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: